Lore Decoster1, Chantal Quinten2, Cindy Kenis3, Johan Flamaing4, Philip R Debruyne5, Inge De Groof6, Christian Focan7, Frank Cornelis8, Vincent Verschaeve9, Christian Bachmann10, Dominique Bron11, Sylvie Luce12, Gwenaëlle Debugne13, Jean-Charles Goeminne14, Abdelbari Baitar15, Katrien Geboers16, Benedicte Petit17, Christine Langenaeken18, Ruud Van Rijswijk19, Pol Specenier20, Guy Jerusalem21, Jean-Philippe Praet22, Katherine Vandenborre23, Jean-Pierre Lobelle24, Michelle Lycke5, Koen Milisen25, Hans Wildiers26. 1. Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: lore.decoster@uzbrussel.be. 2. Laboratory of Experimental Oncology (LEO), Department of Oncology, KU, Leuven, Belgium. 3. Department of General Medical Oncology and Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. 4. Department of Geriatric Medicine, University Hospitals Leuven and Department of Chronic Diseases, Metabolism and Ageing - CHROMETA, KU Leuven, Leuven, Belgium. 5. Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium & Positive Ageing Research Institute (PARI), Anglia Ruskin University, Chelmsford, UK. 6. Department of Geriatric Medicine, Iridium Cancer Network Antwerp, St. Augustinus, Wilrijk, Belgium. 7. Department of Oncology, Clinique Saint-Joseph, CHC-Liège Hospital Group, Liège, Belgium. 8. Department of Medical Oncology, Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium. 9. Department of Medical Oncology, GHDC Grand Hôpital de Charleroi, Charleroi, Belgium. 10. Department of Geriatric Medicine, AZ Sint-Lucas, Gent, Belgium. 11. Department of Hematology, ULB Institut Jules Bordet, Brussels, Belgium. 12. Department Medical Oncology, University Hospital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium. 13. Department of Geriatric Medicine, Centre Hospitalier de Mouscron, Mouscron, Belgium. 14. Department of Medical Oncology, CHU-UCL-Namur, Site Sainte-Elisabeth, Namur, Belgium. 15. Department of Medical Oncology, ZNA Middelheim, Antwerp, Belgium. 16. Centre for Oncology and Hematology, AZ Turnhout, Turnhout, Belgium. 17. Department of Medical Oncology, Centre Hospitalier Jolimont, La Louvière, Belgium. 18. Department Medical Oncology, Iridium Cancer Network Antwerp, AZ Klina, Brasschaat, Belgium. 19. Department Medical Oncology, ZNA Stuivenberg, Antwerp, Belgium. 20. Department of Medical Oncology, University Hospital Antwerp, Antwerp, Belgium. 21. Department of Medical Oncology, Centre Hospitalier Universitaire Sart Tilman and Liege University, Liege, Belgium. 22. Department of Geriatric Medicine, CHU St-Pierre, Free Universities Brussels, Brussels, Belgium. 23. Department of Medical Oncology, AZ Vesalius, Tongeren, Belgium. 24. Consultant in Statistics, Beernem, Belgium. 25. Department of Geriatric Medicine, University Hospitals Leuven, Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium. 26. Department of General Medical Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.
Abstract
OBJECTIVES: This study aims to investigate health-related quality of life (HRQOL) at baseline and at follow-up in older patients with cancer and to determine prognostic factors for HRQOL decline. METHODS: A prospective Belgian multicentre (n = 22) study was performed. Patients ≥70 years with a malignant tumor and abnormal G8 (≤14/17) screening tool were included. Patients underwent geriatric assessment (GA) and HRQOL evaluation with follow up at three months. Uni- and multivariate regression models were performed to determine factors associated (p < .05) with baseline HRQOL and HRQOL decline at follow-up. RESULTS: Results reflect data collected from 3673 patients. A multivariate analysis showed that younger patients, and those with poor Eastern Cooperative Oncology Group - Performance Status (ECOG-PS), specific tumor types (gastrointestinal, gynaecological and thorax) and higher stage had lower baseline HRQOL. In addition worse functional status and presence of pain, fatigue, depression and malnutrition were associated with lower baseline HRQOL. During treatment (n = 2972), improvement in HRQOL was observed in 1037 patients (35%) and a decline in 838 patients (28.2%). In multivariate analysis, stage and presence of baseline comorbidities, pain, fatigue or malnutrition were associated with HRQOL evolution. CONCLUSION: Baseline HRQOL in older patients with cancer and an abnormal G8 depends on tumor and age related parameters. During follow-up, HRQOL improved in one third of patients, indicating that they may benefit from cancer treatment while one quarter demonstrated a HRQOL decline for which prognostic factors were identified.
OBJECTIVES: This study aims to investigate health-related quality of life (HRQOL) at baseline and at follow-up in older patients with cancer and to determine prognostic factors for HRQOL decline. METHODS: A prospective Belgian multicentre (n = 22) study was performed. Patients ≥70 years with a malignant tumor and abnormal G8 (≤14/17) screening tool were included. Patients underwent geriatric assessment (GA) and HRQOL evaluation with follow up at three months. Uni- and multivariate regression models were performed to determine factors associated (p < .05) with baseline HRQOL and HRQOL decline at follow-up. RESULTS: Results reflect data collected from 3673 patients. A multivariate analysis showed that younger patients, and those with poor Eastern Cooperative Oncology Group - Performance Status (ECOG-PS), specific tumor types (gastrointestinal, gynaecological and thorax) and higher stage had lower baseline HRQOL. In addition worse functional status and presence of pain, fatigue, depression and malnutrition were associated with lower baseline HRQOL. During treatment (n = 2972), improvement in HRQOL was observed in 1037 patients (35%) and a decline in 838 patients (28.2%). In multivariate analysis, stage and presence of baseline comorbidities, pain, fatigue or malnutrition were associated with HRQOL evolution. CONCLUSION: Baseline HRQOL in older patients with cancer and an abnormal G8 depends on tumor and age related parameters. During follow-up, HRQOL improved in one third of patients, indicating that they may benefit from cancer treatment while one quarter demonstrated a HRQOL decline for which prognostic factors were identified.
Authors: Sophie C Regueme; Iñaki Echeverria; Nicolas Monéger; Jessica Durrieu; Maïté Becerro-Hallard; Sophie Duc; Aurelie Lafargue; Cécile Mertens; Hamid Laksir; Joël Ceccaldi; Sandrine Lavau-Denes; Thierry Dantoine; Jon Irazusta; Isabelle Bourdel-Marchasson Journal: Support Care Cancer Date: 2020-05-20 Impact factor: 3.603